Merck and NicOx extend research collaboration

While the research, initiated in August 2003, was initially focused on one class of compounds, the two companies have agreed to broaden the field of investigation based on joint preclinical work conducted to date. Additional preclinical studies will be initiated to identify potential lead candidates for development. Merck will make a payment to NicOx in connection with this extension of the agreement.

“We look forward to continuing our collaboration with Merck. We are very pleased with the progress of this important research program, which suggests that nitric oxide-donation could provide potential benefits in an area of considerable medical need,” commented Michele Garufi, chairman and CEO of NicOx.

NicOx is an emerging pharmaceutical company involved in the R&D of nitric oxide-donating drugs with superior efficacy and safety profiles in the inflammation, pain and cardiovascular therapeutic areas.